Flexion Therapeutics Announces Positive Preclinical Data Supporting Development of FX301, a Locally Administered Nav1.7 Inhibitor Product Candidate for Post-Operative PainGlobeNewsWire • 04/27/20
Flexion Therapeutics Announces ZILRETTA® License Agreement and Provides Business Update Amid Coronavirus PandemicGlobeNewsWire • 04/01/20
Pacira (PCRX) Down 37.2% Since Last Earnings Report: Can It Rebound?Zacks Investment Research • 03/21/20
Flexion Therapeutics: Reporting Record Revenue On A Record Day For The MarketSeeking Alpha • 03/19/20
Flexion Therapeutics, Inc. (FLXN) CEO Mike Clayman on Q4 2019 Results - Earnings Call TranscriptSeeking Alpha • 03/13/20
Flexion Therapeutics (FLXN) Reports Q4 Loss, Tops Revenue EstimatesZacks Investment Research • 03/12/20
Flexion Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewsWire • 03/06/20
Pacira BioSciences: Targeting Sales >$1bn By 2025 Despite New Competitive ThreatSeeking Alpha • 02/27/20
Pacira BioSciences, Inc. (PCRX) CEO Dave Stack on Q4 2019 Results - Earnings Call TranscriptSeeking Alpha • 02/20/20
Why the Earnings Surprise Streak Could Continue for Pacira (PCRX)Zacks Investment Research • 02/10/20
Is Pacira Pharmaceuticals (PCRX) Outperforming Other Medical Stocks This Year?Zacks Investment Research • 02/10/20
Pacira BioSciences Launches National Regional Anesthesia Training Initiative with Envision Physician ServicesGlobeNewsWire • 01/21/20